Tessa’s CD30 CAR-T Therapy Receives EMA’s PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma
Shots: The PRIME designation is based on two Phase I/II studies in R/R cHL conducted at Baylor College of Medicine and the University of North Carolina Lineberger Comprehensive Cancer Center The studies showed the complete disappearance of tumors in ~60% of patients at the highest dose level with no serious toxicities, associated with several other […]